- Home
- TARS vs NRXS Comparison
TARS vs NRXS Comparison
Compare TARS & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TARS | NRXS |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 25.8M |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | TARS | NRXS |
|---|---|---|
| Price | $81.80 | $2.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $76.56 | $7.00 |
| AVG Volume (30 Days) | ★ 409.3K | 49.4K |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $366,100,000.00 | $3,362,320.00 |
| Revenue This Year | $147.24 | $31.05 |
| Revenue Next Year | $53.11 | $137.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 182.44 | 36.89 |
| 52 Week Low | $38.51 | $1.33 |
| 52 Week High | $85.25 | $6.20 |
Technical Indicators
Market Signals| Indicator | TARS | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 62.74 | 47.93 |
| Support Level | $78.10 | $2.50 |
| Resistance Level | $85.25 | $2.76 |
| Average True Range (ATR) | 3.08 | 0.15 |
| MACD | -0.28 | 0.02 |
| Stochastic Oscillator | 55.70 | 45.47 |
Price Performance
Historical ComparisonAbout TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).